STOCK TITAN
  1. Home
  2. Sec-filings
  3. SPRY
  4. [144] ARS Pharmaceuticals, Inc. SEC Filing

ARS Pharma holder plans $116K stock sale Sept. 3

ARS Pharmaceuticals, Inc. (SPRY) has a notice from security holder Richard Lowenthal indicating an intention to sell 19,805 shares of common stock under Rule 144.

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
144

Rhea-AI Filing Summary

ARS Pharmaceuticals, Inc. (SPRY) has a notice from security holder Richard Lowenthal indicating an intention to sell 19,805 shares of common stock under Rule 144. The shares are to be sold on September 3, 2026, following a stock option exercise, through Morgan Stanley Smith Barney LLC.

The notice also lists prior Rule 144 sales of ARS Pharmaceuticals common stock by the same holder during the preceding three months, including transactions on August 18, 19, 20, and September 2, 2026, each with specified share amounts and dollar proceeds.

Positive

  • None.

Negative

  • None.
Shares to be sold under Rule 144 19,805 shares Planned Rule 144 sale dated September 3, 2026
Aggregate market value of planned sale $115,564.16 For 19,805 ARS Pharmaceuticals common shares
Shares outstanding 99,447,343 shares ARS Pharmaceuticals common stock outstanding as referenced in the notice
Shares sold on September 2, 2026 840 shares Past 3-month Rule 144 sales for $4,999.76
Shares sold on August 20, 2026 25,000 shares Past 3-month Rule 144 sales for $148,160.00
Shares sold on August 19, 2026 50,000 shares Past 3-month Rule 144 sales for $322,345.00
Shares sold on August 18, 2026 50,000 shares Past 3-month Rule 144 sales for $315,885.00
Rule 144 regulatory
"See the definition of "person" in paragraph (a) of Rule 144."
Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.
stock option exercise financial
"Common | 09/03/2026 | Stock Option Exercise | Issuer"
A stock option exercise is the act of using a previously granted right to buy shares of a company's stock at a specific, predetermined price by paying that price and receiving the shares. It matters to investors because exercising changes who owns the shares (which can dilute existing ownership), can trigger taxable events and shift potential gains or losses, and affects voting power and the company’s outstanding share count—like turning a voucher into an actual product that becomes part of circulating supply.
aggregate market value financial
"Common | Morgan Stanley Smith Barney LLC ... | 19805 | 115564.16"
Aggregate market value is the combined price you would pay to buy all outstanding shares of a company or all companies in a group at current market prices — essentially the sum of each stock’s market capitalization. It matters to investors because it shows the overall size and weight of an investment or sector (like the total cost to buy every piece of a puzzle), helps compare scale across companies or markets, and influences index composition and risk exposure.

FAQ

What does the Form 144 filing disclose for ARS Pharmaceuticals (SPRY)?
It discloses that Richard Lowenthal plans to sell 19,805 shares of ARS Pharmaceuticals common stock under Rule 144 on September 3, 2026, following a stock option exercise and through Morgan Stanley Smith Barney LLC.

How many ARS Pharmaceuticals (SPRY) shares are planned to be sold under this Form 144?
The filing states an intention to sell 19,805 shares of common stock of ARS Pharmaceuticals in a planned Rule 144 transaction dated September 3, 2026.

What is the aggregate market value of the SPRY shares covered by this Form 144?
The Form 144 lists an aggregate market value of $115,564.16 for the 19,805 shares of ARS Pharmaceuticals common stock proposed to be sold.

What prior ARS Pharmaceuticals (SPRY) sales by this holder are listed in the last 3 months?
The notice lists sales of 840 shares for $4,999.76 on September 2, 2026; 25,000 shares for $148,160.00 on August 20, 2026; 50,000 shares for $322,345.00 on August 19, 2026; and 50,000 shares for $315,885.00 on August 18, 2026.

How many ARS Pharmaceuticals (SPRY) shares are reported as outstanding in this notice?
The Form 144 reports that 99,447,343 shares of ARS Pharmaceuticals common stock were outstanding, providing context for the planned Rule 144 sale; this is a baseline figure, not the amount being sold.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

Source: View Original Filing on SEC EDGAR